STAGE III LUNG CANCER AJCC V8

This study is for people with inoperable, locally advanced non-small cell lung cancer. It compares the current standard treatment (chemotherapy plus standard radiation, followed by a year of immunotherapy or targeted pills) against a new approach that adds a short, intense burst …

This early-stage study is testing the safety of a personalized vaccine designed to train a patient's immune system to attack their specific cancer. It is for adults with advanced breast cancer, melanoma, or non-small cell lung cancer that has continued to grow despite standard tr…

This study is testing if adding diclofenac, a common anti-inflammatory painkiller, can help control advanced lung cancer that is starting to get worse while patients are on standard immunotherapy. The goal is to see if diclofenac can slow tumor growth and make the immunotherapy w…

This study is for people with stage III non-small cell lung cancer that has started to grow again (progressed) after their initial chemo-radiation and immunotherapy. It tests whether using targeted treatments like surgery or radiation to attack specific progressing tumors, follow…

This study is testing whether adding a new drug called GT103 to an existing immunotherapy (pembrolizumab) can better control advanced lung cancer that has a specific genetic change (STK11 mutation). The trial is for patients whose cancer has continued to grow despite prior treatm…

This study is testing whether updating radiation treatment plans at set times during therapy can reduce damage to healthy heart and lung tissue in people with non-small cell lung cancer. Researchers want to see if this adaptive approach lowers side effects like lung inflammation …

This study is testing whether adding an experimental drug called TRC102 to standard treatment helps people with stage III non-squamous non-small cell lung cancer live longer without their cancer getting worse. About 42 participants will receive either the standard treatment (chem…

This study is testing whether giving two immunotherapy drugs before surgery can help the body's immune system attack and shrink early-stage non-small cell lung cancer. The goal is to kill more cancer cells before the tumor is removed, potentially leading to better long-term resul…

This study is testing whether combining two targeted cancer drugs is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The trial is for patients whose cancer has continued to grow despite previous treatment…

This study is testing a new, personalized vaccine designed to target the unique proteins on a patient's own cancer cells. It is being given alongside an existing immunotherapy drug (pembrolizumab) to see if the combination is safe and can help control advanced solid tumors that h…

This study is testing if a drug called canakinumab can prevent lung cancer in people who have suspicious, high-risk spots (nodules) in their lungs. About 50 participants will receive injections of the drug every 3 weeks for up to 8 cycles. The main goal is to see if the drug can …

This study is testing whether a yoga program for patients and their caregivers can improve physical function and quality of life during radiation treatment for lung or esophageal cancer. It will compare yoga sessions to educational sessions to see which helps patients walk farthe…

This study is testing whether a home-based breathing exercise program can help people who have had early-stage lung cancer. Many survivors experience shortness of breath and fatigue after treatment, which makes it hard to stay active. Researchers want to see if strengthening brea…

This study is testing whether a special communication tool helps doctors and patients with non-small cell lung cancer make treatment decisions together more effectively. The tool guides conversations about treatment options, benefits, and risks while considering each patient's pe…

This study aims to understand how radiation and chemotherapy for advanced lung cancer affects heart health over time. Researchers will follow 100 patients receiving personalized treatment plans, measuring heart fitness and injury markers before, during, and for years after treatm…

This study aims to understand if the order a surgeon cuts the blood vessels during lung cancer surgery affects how much cancer DNA is left in the bloodstream afterward. Researchers will compare two standard techniques—cutting the vein first versus cutting the artery first—in 100 …

This study aims to understand why some patients with advanced cancers like melanoma and lung cancer respond well to a common immunotherapy (anti-PD-1), while others do not. Researchers will collect blood samples from 500 patients to measure specific markers in immune cells during…

This study is collecting tissue and blood samples from cancer patients over time to create a research resource called a biobank. Researchers will analyze these samples to understand how cancer changes during treatment and why some treatments stop working. The goal is to help scie…

This study aims to understand why some cancer patients develop severe diarrhea and colon inflammation (colitis) while taking powerful immunotherapy drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 patients with melanoma…